Table 3 Association of CYP2D6 testing and therapeutic decision-making by CYP2D6 phenotypes
From: Pharmacogenetic testing affects choice of therapy among women considering tamoxifen treatment
CYP2D6phenotype | Still on tamoxifen | Changed to AIs | No therapy | Total | P a | Taking co-medications | Changed co-medication | P a |
|---|---|---|---|---|---|---|---|---|
Ultra-rapid (UM)/extensive metabolizer (EM)b | 156 (84%) | 10 (5%) | 20 (11%) | 186 | Â | 38 (21%) | 9 (5%) | Â |
Intermediate metabolizer (IM) | 28 (88%) | 1 (3%) | 3 (9%) | 32 | 0.51 | 8 (25%) | 2 (3%) | 0.62 |
Poor metabolizer (PM) | 4 (31%) | 6 (46%) | 3 (23%) | 13 | < 0.001 | 0 | 0 | - |
Total | 188 | 17 | 26 | 231 | Â | 46 | 11 | Â |